Evaxion Biotech A/S — Form 6-K Summary
Business Context and Reporting Period
Evaxion Biotech A/S, a Danish foreign private issuer, furnished this Form 6-K for May 2021. The filing is dated May 12, 2021 and reports a corporate-governance change rather than financial results.
Governance Change
- Steven Projan, an existing board member, was appointed to the Nomination and Corporate Governance Committee effective May 12, 2021.
- The committee now consists of Marianne Søgaard, Roberto Prego, and Steven Projan.
- The board determined that Roberto Prego and Steven Projan qualify as independent directors under applicable SEC and Nasdaq rules.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, balance-sheet data, or other operating metrics.
Outlook, Risks, and Unusual Items
The filing provides no guidance, outlook, management discussion, risk updates, contingencies, or unusual financial items.
Important Facts to Verify
- Verify the composition and independence determinations of the Nomination and Corporate Governance Committee.
- Review subsequent SEC filings for financial results, liquidity, financing activity, and business or clinical developments.
- Note that the report is incorporated by reference into the Company’s Form S-8 registration statement, to the extent not superseded by later filings.